IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,485,000 | -35.4% | 6,700,000 | 0.0% | 0.48% | -25.8% |
| Q2 2023 | $47,168,000 | +10.0% | 6,700,000 | -4.6% | 0.64% | +0.6% |
| Q1 2023 | $42,892,200 | -4.4% | 7,020,000 | 0.0% | 0.64% | -5.1% |
| Q4 2022 | $44,857,800 | -48.1% | 7,020,000 | -22.2% | 0.67% | -58.0% |
| Q3 2022 | $86,412,000 | -15.1% | 9,020,000 | -2.2% | 1.60% | -20.6% |
| Q2 2022 | $101,789,000 | -33.0% | 9,220,000 | +1.0% | 2.01% | -27.5% |
| Q1 2022 | $151,931,000 | -8.3% | 9,125,000 | +5.2% | 2.77% | -1.6% |
| Q4 2021 | $165,606,000 | -21.6% | 8,675,000 | -5.2% | 2.82% | -15.0% |
| Q3 2021 | $211,150,000 | -10.8% | 9,150,000 | +0.5% | 3.32% | -19.5% |
| Q2 2021 | $236,782,000 | -6.5% | 9,100,000 | +13.8% | 4.12% | -5.8% |
| Q1 2021 | $253,280,000 | -27.2% | 8,000,000 | +6.7% | 4.37% | -27.0% |
| Q4 2020 | $348,000,000 | +10.9% | 7,500,000 | -21.4% | 5.99% | +34.4% |
| Q3 2020 | $313,926,000 | +10.4% | 9,536,039 | -8.0% | 4.46% | -20.7% |
| Q2 2020 | $284,411,000 | +4.2% | 10,361,039 | +1.0% | 5.62% | -38.9% |
| Q1 2020 | $272,852,000 | +11.7% | 10,260,413 | +16.3% | 9.21% | +28.4% |
| Q4 2019 | $244,305,000 | +26.6% | 8,826,039 | -16.7% | 7.17% | -10.9% |
| Q3 2019 | $192,939,000 | -26.8% | 10,601,039 | -1.4% | 8.05% | -11.7% |
| Q2 2019 | $263,653,000 | +163.3% | 10,752,585 | +2.1% | 9.11% | +110.4% |
| Q1 2019 | $100,148,000 | +10.3% | 10,530,862 | +2.6% | 4.33% | -20.2% |
| Q4 2018 | $90,810,000 | -6.8% | 10,261,039 | +18.5% | 5.43% | +21.3% |
| Q3 2018 | $97,456,000 | -6.9% | 8,662,720 | +5.9% | 4.48% | +11.0% |
| Q2 2018 | $104,675,000 | -23.3% | 8,177,720 | +1.2% | 4.03% | -38.2% |
| Q1 2018 | $136,527,000 | +224.8% | 8,078,505 | +53.8% | 6.52% | +139.4% |
| Q4 2017 | $42,028,000 | +29.1% | 5,253,450 | +25.0% | 2.72% | +7.9% |
| Q3 2017 | $32,560,000 | +6.7% | 4,201,343 | +1.2% | 2.52% | -34.5% |
| Q2 2017 | $30,512,000 | – | 4,151,343 | – | 3.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |